Tecentriq

IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with…

The findings are the first indication of how well Lumakras works in combination with drugs that help the immune system attack…

The approval marks Tecentriq’s sixth lung cancer indication in Europe

The study evaluating Tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival

The Skyscraper-II trial was the first to produce results in the final stage of clinical testing in a class of drugs known as…

The company announced several key development milestones in neuroscience, ophthalmology, oncology and COVID-19, along with some…

As published in The Lancet, Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the…

Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting…

Many new therapies entering the market have different mechanisms of action (MOA) and are aiming to meet needs in different…

The recommendation from the CHMP is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in…